Logo

AYTU

Aytu BioPharma, Inc.

AYTU

Aytu BioPharma, Inc. • NASDAQ
$2.19 ▲ 4.29% (+0.09)
Market Cap $15.60 M
52w High $2.82
52w Low $0.95
Dividend Yield 0%
P/E -0.98
Volume 21.24K
Outstanding Shares 7.12M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q1-2026 $13.888M ▼ $10.69M ▼ $1.965M ▲ 14.149% ▲ $-0.08 ▲ $3.284M ▲
Q4-2025 $15.135M ▼ $17.877M ▲ $-19.818M ▼ -130.942% ▼ $-2.92 ▼ $-17.419M ▼
Q3-2025 $18.452M ▲ $10.385M ▼ $3.994M ▲ 21.645% ▲ $0.65 ▲ $6.035M ▲
Q2-2025 $16.221M ▼ $12.481M ▼ $788K ▼ 4.858% ▼ $0.02 ▼ $2.634M ▼
Q1-2025 $16.574M $12.915M $1.474M 8.893% $0.2 $3.919M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q1-2026 $32.63M ▲ $124.988M ▲ $101.817M ▼ $23.171M ▲
Q4-2025 $30.952M ▲ $124.177M ▼ $105.211M ▲ $18.966M ▼
Q3-2025 $18.173M ▼ $124.201M ▲ $89.303M ▲ $34.898M ▲
Q2-2025 $20.398M ▲ $116.227M ▲ $85.462M ▼ $30.765M ▲
Q1-2025 $20.108M $115.831M $86.005M $29.826M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q1-2026 $1.965M ▲ $-618K ▼ $0 ▲ $2.296M ▼ $1.678M ▼ $-618K ▼
Q4-2025 $-19.88M ▼ $2.803M ▲ $-3.017M ▼ $12.993M ▲ $12.779M ▲ $2.786M ▲
Q3-2025 $3.994M ▲ $-6.455M ▼ $-69K ▼ $4.299M ▲ $-2.225M ▼ $-6.524M ▼
Q2-2025 $788K ▼ $2.905M ▲ $145K ▼ $-2.76M ▼ $290K ▲ $2.899M ▲
Q1-2025 $1.474M $-1.19M $381K $911K $102K $-1.326M

Revenue by Products

Product Q1-2024Q2-2024Q3-2024Q4-2024
Consumer Health
Consumer Health
 $0 ▲$0 ▲$0 ▲$10.00M ▲
Other
Other
 $0 ▲$0 ▲$0 ▲$0 ▲
Pediatric
Pediatric
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Aytu’s income statement shows a small but growing revenue base with generally healthy gross margins for a specialty pharma company. Operating losses have narrowed sharply over the last few years, moving from heavy losses toward something much closer to break-even. This suggests tighter cost control, a better product mix, and a clearer focus on higher-margin prescription drugs. That said, the company is still not consistently profitable, and earnings per share have been very volatile, partly because of repeated changes to the share structure. Overall, the trend is improving, but profitability remains fragile and highly dependent on successful commercialization of its core products.

Balance Sheet

Balance Sheet The balance sheet is light, reflecting a small company with limited assets and a thin equity cushion. Cash on hand is modest but present, and total debt is relatively low, which reduces financial strain from interest payments. However, the small equity base means there is not a lot of room to absorb major setbacks. The long history of reverse stock splits is a sign that the company has faced ongoing market-cap and dilution pressures over time, likely tied to repeated capital-raising. Financially, Aytu appears lean but not heavily leveraged, with limited safety margins.

Cash Flow

Cash Flow Historically, Aytu has been a cash-burning business, as is common for small pharma companies, but its cash outflow from operations has improved and is now hovering around roughly breakeven. Capital spending needs are very low, so free cash flow largely mirrors operating cash flow. This is helpful, but it also means that any slip in revenue or uptick in expenses can quickly push the company back into more meaningful cash burn. Future cash health will depend heavily on the ramp of new and existing products, along with disciplined spending on sales and marketing rather than large, speculative R&D programs.

Competitive Edge

Competitive Edge Aytu operates in crowded therapeutic areas, but it has carved out defensible niches. Its ADHD portfolio uses orally disintegrating, extended-release tablets that are unique in the market, particularly appealing for children and patients who struggle with swallowing traditional pills. The company has also distinguished itself by maintaining reliable product supply during broader ADHD drug shortages, which has helped build goodwill with prescribers and patients. The RxConnect access program further improves patient affordability and loyalty. Still, Aytu competes against much larger pharmaceutical players with deeper pockets, so its advantages rest on differentiation, execution, and service quality rather than sheer scale.

Innovation and R&D

Innovation and R&D Innovation at Aytu is now centered more on differentiated commercial products than on a broad internal pipeline. The key near-term innovation is Exxua, a novel antidepressant with a unique mechanism and a potentially more favorable side-effect profile in areas that matter to patients, such as sexual function and weight. Its ADHD ODT technology is also a meaningful formulation innovation, making treatment easier for pediatric and other patients. On the other hand, the suspension of the AR101 program shows a clear pullback from expensive late-stage development. This reduces upfront R&D risk and spending but also leaves a thinner pipeline and increases dependence on the success of a small number of marketed or near-market drugs, with future product additions likely coming more from deals than from in-house discovery.

Summary

Aytu BioPharma is a small, specialized pharmaceutical company transitioning from a heavier R&D and consumer-health past toward a focused prescription model in CNS and pediatric care. Financially, it has moved from significant losses toward operating near breakeven, with acceptable margins but still no steady profitability and only a modest cash cushion. The balance sheet is light but not heavily indebted, leaving limited room for missteps. Competitively, Aytu’s strength lies in niche, patient-friendly formulations, a differentiated new antidepressant, and support programs that improve access and adherence, all within markets that are otherwise dominated by much larger firms. The main opportunities revolve around successful scaling of Exxua and continued gains in ADHD during supply-constrained periods, while key risks include intense competition, pricing and reimbursement pressures, and the possibility of needing additional capital if growth or uptake of key products falls short of expectations.

NEWS

November 24, 2025 · 4:05 PM UTC

Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference

Read more

November 13, 2025 · 4:05 PM UTC

Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results

Read more

November 5, 2025 · 4:05 PM UTC

Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025

Read more

October 28, 2025 · 9:00 AM UTC

Aytu BioPharma Announces Patent Term Extension for EXXUA(TM)

Read more

October 10, 2025 · 9:00 AM UTC

Aytu BioPharma to Present at Upcoming October 2025 Conferences

Read more